title: The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation.
abstract: Balancing immunogenicity with inflammation is a central tenet of vaccine design, especially for subunit vaccines that utilize traditional pro-inflammatory adjuvants. Here we report that by using a nanoparticulate peptide-based vaccine, immunogenicity and local inflammation could be decoupled. Self-assembled β-sheet-rich peptide nanofibers, previously shown to elicit potent antibody responses in mice, were found to be non-cytotoxic in vitro and, remarkably, elicited no measurable inflammation in vivo-with none of the swelling at the injection site, accumulation of inflammatory cells or cytokines, or production of allergic IgE that were elicited by an alum-adjuvanted vaccine. Nanofibers were internalized by dendritic cells and macrophages at the injection site, and only dendritic cells that acquired the material increased their expression of the activation markers CD80 and CD86. Immunization with epitope-bearing nanofibers elicited antigen-specific differentiation of T cells into T follicular helper cells and B cells into germinal center cells, as well as high-titer, high-affinity IgG that cross-reacted with the native protein antigen and was neutralizing in an in vitro influenza hemagglutination inhibition assay. These responses were superior to those induced by alum and comparable to those induced by complete Freund's adjuvant. Thus, nanoparticulate assemblies may provide a new route to non-inflammatory immunotherapies and vaccines.
authors: Committee on Immunology, Department of Surgery, The University of Chicago, Chicago, IL 60637, USA.
authors: Jianjun
authors: J
authors: Chen
authors: Rebecca R
authors: RR
authors: Pompano
authors: Felix W
authors: FW
authors: Santiago
authors: Lea
authors: L
authors: Maillat
authors: Roger
authors: R
authors: Sciammas
authors: Tao
authors: T
authors: Sun
authors: Huifang
authors: H
authors: Han
authors: David J
authors: DJ
authors: Topham
authors: Anita S
authors: AS
authors: Chong
authors: Joel H
authors: JH
authors: Collier
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000534:Alum Compounds / Q000737:chemistry; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D001402:B-Lymphocytes / Q000276:immunology*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D001672:Biocompatible Materials / Q000737:chemistry; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D007249:Inflammation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D057139:Nanofibers / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D022223:Vaccines, Subunit / Q000737:chemistry* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D001672:Biocompatible Materials; D016207:Cytokines; D000939:Epitopes; D010455:Peptides; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D022223:Vaccines, Subunit; C041524:aluminum sulfate
keywords: Alum adjuvant; Nanoparticle vaccines; Non-reactogenic; OVA(323-339) peptide; Self assembly
references: J Infect Dis. 2011 Dec 15;204(12):1879-85
references: 21998477
references: PLoS One. 2010 Mar 23;5(3):e9809
references: 20352110
references: Nat Med. 2011 Jul 17;17(8):996-1002
references: 21765404
references: Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):622-7
references: 20080728
references: Biomaterials. 2008 May;29(13):2143-51
references: 18261790
references: J Control Release. 2012 Feb 10;157(3):354-65
references: 21820024
references: J Immunol. 2009 Oct 1;183(7):4403-14
references: 19734227
references: Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17585-90
references: 23045649
references: Adv Mater. 2012 Jul 24;24(28):3845-9
references: 22550019
references: Sci Rep. 2011;1:198
references: 22355713
references: Biomaterials. 2009 Apr;30(12):2400-10
references: 19203790
references: Vaccine. 2010 Nov 23;28(50):7897-906
references: 20934457
references: Vaccine. 1997 Aug-Sep;15(12-13):1364-71
references: 9302746
references: Vaccine. 2013 Jan 11;31(4):653-60
references: 23200935
references: Trends Immunol. 2006 Dec;27(12):573-9
references: 17049307
references: J Exp Med. 2008 Apr 14;205(4):869-82
references: 18362170
references: Soft Matter. 2008;4(12):2310-2315
references: 20198120
references: Adv Healthc Mater. 2013 Feb;2(2):369-78
references: 23184561
references: Adv Mater. 2012 Jul 24;24(28):3724-46
references: 22641380
references: Vaccine. 2009 Oct 9;27(43):5956-63
references: 19679214
references: Biomaterials. 2011 Oct;32(28):6815-22
references: 21703679
references: J Am Chem Soc. 2012 May 30;134(21):8730-3
references: 22587010
references: ACS Nano. 2012 Feb 28;6(2):1557-64
references: 22273009
references: Annu Rev Immunol. 2011;29:621-63
references: 21314428
references: Acta Biomater. 2011 Jul;7(7):2857-64
references: 21439412
references: Biomaterials. 2012 Sep;33(27):6476-84
references: 22695068
references: Front Immunol. 2013 Jan 10;3:406
references: 23335921
references: Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1080-5
references: 22247289
references: Trends Immunol. 2009 Jan;30(1):23-32
references: 19059004
references: Nat Biotechnol. 2007 Oct;25(10):1159-64
references: 17873867
references: Integr Biol (Camb). 2011 Mar;3(3):185-96
references: 21249249
references: J Pharm Sci. 2008 Mar;97(3):1155-64
references: 17683059
references: Vaccine. 2011 Feb 17;29(9):1812-23
references: 21215831
references: Vaccine. 2004 Nov 25;23(2):258-66
references: 15531045
references: Biol Chem. 2008 May;389(5):521-36
references: 18953718
references: Adv Drug Deliv Rev. 1998 Jul 6;32(3):155-172
references: 10837642
references: Curr Drug Deliv. 2011 May;8(3):282-9
references: 21291373
references: Vaccine. 2007 May 10;25(19):3752-62
references: 17336431
references: Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11169-74
references: 21690334
references: PLoS One. 2011 Jan 26;6(1):e16333
references: 21298114
references: ACS Nano. 2012 Mar 27;6(3):2136-49
references: 22303914
references: Expert Rev Vaccines. 2009 Apr;8(4):483-92
references: 19348563
references: Curr Drug Targets. 2002 Apr;3(2):175-96
references: 11958299
references: Sci Transl Med. 2012 Aug 22;4(148):148rv9
references: 22914624
references: Nat Rev Immunol. 2010 Nov;10(11):787-96
references: 20948547
references: J Immunol. 2009 Dec 1;183(11):7268-77
references: 19915055
references: Nat Rev Drug Discov. 2007 May;6(5):404-14
references: 17473845
references: Influenza Other Respir Viruses. 2008 Nov;2(6):243-9
references: 19453401
references: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2764-9
references: 16473934
references: PLoS One. 2011 Mar 03;6(3):e17642
references: 21408610
references: Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):870-5
references: 19139407
references: Curr Opin Immunol. 2007 Jun;19(3):268-74
references: 17433875
references: Biomaterials. 2011 Mar;32(8):2194-203
references: 21183216
references: PLoS One. 2012;7(10):e48304
references: 23144750
references: Biomaterials. 2012 Oct;33(29):7221-32
references: 22796161
references: J Pharm Sci. 2008 Jun;97(6):2041-4
references: 17847072